2026 ICD-10-CM Diagnosis Code C88.00Waldenstrom macroglobulinemia not having achieved remission

ICD-10-CM Codes›C00–D49›C81-C96›C88

ICD-10-CM C88.00
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

C88.00 is a billable ICD-10-CM diagnosis code for waldenstrom macroglobulinemia not having achieved remission. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 820 through 825, 840 through 842. Coders also document this condition as macroglobulinemia. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Non-Hodgkin lymphoma.

Code Identity

ICD-10-CM Code
C88.00
Billable Status
Yes — Valid for Submission
Code Describes
Waldenstrom macroglobulinemia not having achieved remission
Short Description
Waldenstrom macroglobulinemia not having achieved remission
Same as the full description in the CMS dataset.
Parent Code
C88.0
Waldenstrom macroglobulinemia

Code Classification

ChapterC00–D49Neoplasms
SectionC81-C96Malignant neoplasms of lymphoid, hematopoietic and related tissue
CategoryC88Malignant immunoproliferative diseases and certain other B-cell lymphomas
This CodeC88.00Waldenstrom macroglobulinemia not having achieved remission

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Macroglobulinemia
  • Macroglobulinemic nephropathy
  • Malignant lymphoma - lymphoplasmacytic
  • Neuropathy associated with dysproteinemias
  • Neuropathy in macroglobulinemia
  • Renal involvement in malignant disease
  • Waldenström macroglobulinemia

Tabular List NotesGuidance

Coding notes and annotation back-references applicable to this code.

Inclusion Terms

  • Lymphoplasmacytic lymphoma with IgM-production, NOS
  • Lymphoplasmacytic lymphoma with IgM-production not having achieved remission
  • Lymphoplasmacytic lymphoma with IgM-production with failed remission
  • Macroglobulinemia (idiopathic) (primary) NOS
  • Macroglobulinemia (idiopathic) (primary) not having achieved remission
  • Macroglobulinemia (idiopathic) (primary) with failed remission
  • Waldenström macroglobulinemia NOS
  • Waldenström macroglobulinemia with failed remission

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO058
Non-Hodgkin lymphoma
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Waldenstrom Macroglobulinemia

    a lymphoproliferative disorder characterized by pleomorphic b-lymphocytes including plasma cells, with increased levels of monoclonal serum immunoglobulin m. there is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. clinical features include anemia; hemorrhages; and hyperviscosity.

Code History & ChangesHistory

Replacement C88.00 replaces the following previously assigned code(s):

  • C88.0 - Waldenstrom macroglobulinemia
FY 2025AddedAdded to the ICD-10-CM code setEffective October 1, 2024.
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About C88.00Overview

Is C88.00 (Waldenstrom macroglobulinemia) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report waldenstrom macroglobulinemia not having achieved remission on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does C88.00 group to?

When waldenstrom macroglobulinemia not having achieved remission is the principal diagnosis on an inpatient stay, it groups to MS-DRG 820, 821, 822, 823, 824, 825, 840, 841, 842, with relative weights from 1.0104 to 5.8648 depending on complications. Higher weights mean higher Medicare reimbursement.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.